The End of the Daily Pill? How a $9.6M Gates Grant Could Redefine HIV Prevention

BRADENTON, Fla. – October 14, 2026 — Despite decades of staggering biomedical advancements, the global fight against HIV continues to collide with a stubbornly human obstacle: adherence. According to UNAIDS, 2025 saw 1.2 million new HIV infections worldwide. The tragedy of this statistic lies not in a lack of effective science, but in the systemic and behavioral friction of delivering that science consistently. Today, Continuity Biosciences, a clinical-stage biotechnology firm, announced a significant leap toward eliminating that friction, securing a grant of up to $9.6 million from the Bill & Melinda Gates Foundation to advance a subcutaneous, ultra-long-acting antiretroviral implant for HIV pre-exposure prophylaxis (PrEP).

Designed to deliver continuous protection for multiple years from a single placement, the implant targets a critical vulnerability in global health infrastructure. By replacing daily oral regimens and periodic injections with a multi-year device, the Florida-based company is pioneering a structural shift in how we approach infectious disease prevention. The funding will propel the company’s nanofluidic drug delivery platform through Investigational New Drug (IND)-enabling preclinical studies, an IND regulatory filing, and the initiation of a first-in-human Phase 1 clinical trial.

For those of us tracking the intersection of institutional innovation and community health, this development represents a profound recalibration of the HIV prevention landscape. It acknowledges a fundamental truth: true health equity requires interventions that demand less from the populations they are meant to protect.

The End of Daily Pills: Closing the Prevention Gap

The current arsenal of HIV prevention is highly effective but logistically demanding. Daily oral PrEP works exceptionally well when taken as prescribed, yet sustaining daily adherence over months and years remains a high hurdle for many. Recent innovations have introduced long-acting injectables, such as the bi-monthly cabotegravir (Apretude) and the ultra-long-acting lenacapavir (Sunlenca), which is currently under investigation for bi-yearly PrEP use.

However, even a twice-a-year injection requires a dependable supply chain, clinical infrastructure, and a patient's ability to take time away from work or family to visit a healthcare provider. In low- and middle-income countries (LMICs), these logistical requirements often translate into insurmountable barriers.

"For many people, the challenge in HIV prevention is not the availability of effective medicines, but the burden of staying protected consistently over time," said Ramakrishna "Krishna" Venugopalan, PhD, MBA, Co-Founder and Chief Executive Officer of Continuity Biosciences. "A prevention option designed to provide protection for years could fundamentally change what is possible, particularly in communities where access to healthcare is limited."

A single-placement implant that functions for years circumvents the behavioral fatigue associated with daily pills and the logistical strain of recurring clinical visits. It shifts the paradigm of HIV prevention from an active, ongoing responsibility to a passive, durable state of protection.

Nanofluidics Under the Skin: Engineering Precision

The core of this multi-year promise lies in the company's proprietary nanofluidic drug delivery technology. Unlike traditional long-acting injectables that rely on a bolus dose slowly dispersing through systemic circulation—often resulting in declining drug concentrations over time—the implant utilizes a precisely engineered membrane with nanoscale channels.

This architecture is designed to achieve zero-order kinetics, meaning the antiretroviral drug diffuses at a constant, steady rate. The drug reservoir is protected from enzymatic degradation, ensuring the therapeutic agent remains stable and active over its multi-year lifespan. Constructed from highly biocompatible materials like silicon and titanium, the device is surgically placed under the skin and can be retrieved if treatment needs to be halted or the device requires replacement.

"Our nanofluidic implant was engineered around a simple idea: HIV prevention shouldn't depend on remembering a daily pill or the next appointment," said Alessandro Grattoni, PhD, Co-Founder and Chief Scientific Advisor of Continuity Biosciences. "By controlling drug release at the device level, we aim to sustain constant ARV delivery for multiple years from a single implant. This support allows us to move that science from the laboratory toward a first-in-human evaluation."

The engineering principles driving this HIV PrEP implant are not limited to infectious diseases. Continuity is already leveraging this precision delivery platform across other therapeutic areas, including type 1 diabetes, endocrinology, and oncology, where an ongoing first-in-human study is evaluating an iontophoretic platform for pancreatic cancer.

Navigating a Complex Regulatory Path

Transitioning a multi-year implant from the laboratory to the clinic involves navigating a highly rigorous regulatory environment. Because the implant combines a mechanical device with a pharmacological agent, the FDA classifies it as a drug-device combination product. This necessitates joint oversight from both the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH).

The $9.6 million Gates Foundation grant is earmarked for the critical, data-heavy phases of this journey. IND-enabling studies will require extensive toxicology, pharmacology, and biocompatibility testing in animal models. Regulatory bodies will demand exhaustive proof that the device does not trigger severe inflammatory responses over time and that the drug release remains perfectly consistent without the risk of "dose dumping"—a dangerous scenario where a device releases its payload all at once.

"When you design a device meant to reside in the subcutaneous space for years, the regulatory scrutiny rightly demands impeccable data on both the drug's stability and the device's mechanical integrity," noted an independent biomedical regulatory consultant familiar with long-acting implants. "The field has seen previous setbacks with long-acting PrEP implants due to unexpected physiological responses, so the safety data generated in these early stages will dictate the entire future of the platform."

Philanthropic Capital as a Catalyst for Global Equity

Perhaps as vital as the nanofluidic engineering is the financial architecture supporting it. The involvement of the Bill & Melinda Gates Foundation brings more than just capital; it introduces a mandate for global health equity through its Global Access commitments.

Typically, the biotechnology sector is driven by the pursuit of lucrative Western markets, with LMICs receiving access to life-saving innovations years, or even decades, after initial commercialization. The Gates Foundation's funding model flips this paradigm, employing an "LMIC-first" strategy. By providing early-stage, non-dilutive capital, the foundation de-risks the costly preclinical and Phase 1 development phases. In exchange, Continuity Biosciences is legally bound to make the resulting technology available at an affordable price to populations most in need in developing nations, alongside broad commitments to share the knowledge generated by the program.

This framework ensures that if the ultra-long-acting implant proves successful, it will not become a luxury prevention tool reserved for high-income nations. Instead, it will be primed for deployment in the regions that account for the vast majority of the 1.2 million new HIV infections recorded last year. For a clinical-stage biotech company, balancing commercial viability with immediate global access is a complex high-wire act, but philanthropic partnerships of this scale provide the necessary safety net to prioritize human impact over immediate margins.